Lozano Rabella, MariaGarcia Garijo, AndreaPalomero, JaraYuste Estevanez, AnnaErhard, FlorianFarriol Duran, RocMartín Liberal, JuanOchoa de Olza, MariaMatos, IgnacioGartner, Jared J.Ghosh, MichaelCanals, FrancescVidal, AugustPiulats, Josep M.Matias-Guiu, Xavier, 1958-Brana, IreneMuñoz Couselo, EvaGarralda, ElenaSchlosser, AndreasGros Vidal, Alena2023-07-242023-07-242023-02-071557-3265https://hdl.handle.net/2445/201061Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated the immunogenicity of nonC tumor HLA-I ligands (nonC-TL) to better understand their contribution to cancer immunosurveillance and their therapeutic applicability. Experimental Design: Peptides presented on HLA-I were iden-tified in 9 patient-derived tumor cell lines from melanoma, gyneco-logic, and head and neck cancer through proteogenomics. A total of 507 candidate tumor antigens, including nonC-TL, neoantigens, cancer-germline, or melanocyte differentiation antigens, were tested for T-cell recognition of preexisting responses in patients with cancer. Donor peripheral blood lymphocytes (PBL) were in vitro sensitized against 170 selected nonC-TL to isolate antigen-specific T-cell recep-tors (TCR) and evaluate their therapeutic potential.Rudolf Virchow Center, Center for Integrative and Transla- tional Bioimaging, Julius-Maximilians-University Wueurorzburg, Wueurorzburg, Germany16 p.application/pdfengcc by-nc-nd (c) Lozano Rabella, Maria et al, 2023http://creativecommons.org/licenses/by-nc-nd/3.0/es/Antígens HLAProteòmicaGenòmicaHLA histocompatibility antigensProteomicsGenomicsinfo:eu-repo/semantics/article2023-07-21info:eu-repo/semantics/openAccess36749875